1. Karpman D, Ståhl AL, Arvidsson I. Extracellular vesicles in renal disease.
Nat Rev Nephrol 2017;13:545–562.
2. Todorova D, Simoncini S, Lacroix R, Sabatier F, Dignat-George F. Extracellular vesicles in angiogenesis.
Circ Res 2017;120:1658–1673.
3. Lipschutz JH. The role of the exocyst in renal ciliogenesis, cystogenesis, tubulogenesis, and development.
Kidney Res Clin Pract 2019;38:260–266.
4. Linxweiler J, Junker K. Extracellular vesicles in urological malignancies: an update.
Nat Rev Urol 2020;17:11–27.
5. Jing H, Tang S, Lin S, Liao M, Chen H, Zhou J. The role of extracellular vesicles in renal fibrosis.
Cell Death Dis 2019;10:367.
6. Kwon SH. Extracellular vesicles in renal physiology and clinical applications for renal disease.
Korean J Intern Med 2019;34:470–479.
7. Takahashi A, Okada R, Nagao K, et al. Exosomes maintain cellular homeostasis by excreting harmful DNA from cells.
Nat Commun 2017;8:15287.
8. Borges FT, Melo SA, Özdemir BC, et al. TGF-β1-containing exosomes from injured epithelial cells activate fibroblasts to initiate tissue regenerative responses and fibrosis.
J Am Soc Nephrol 2013;24:385–392.
9. Yáñez-Mó M, Siljander PR, Andreu Z, et al. Biological properties of extracellular vesicles and their physiological functions.
J Extracell Vesicles 2015;4:27066.
10. Ståhl AL, Johansson K, Mossberg M, Kahn R, Karpman D. Exosomes and microvesicles in normal physiology, pathophysiology, and renal diseases.
Pediatr Nephrol 2019;34:11–30.
11. Segura E, Nicco C, Lombard B, et al. ICAM-1 on exosomes from mature dendritic cells is critical for efficient naive T-cell priming.
Blood 2005;106:216–223.
12. Clayton A, Mitchell JP, Court J, Mason MD, Tabi Z. Human tumor-derived exosomes selectively impair lymphocyte responses to interleukin-2.
Cancer Res 2007;67:7458–7466.
13. Guo X, Qiu W, Liu Q, et al. Immunosuppressive effects of hypoxia-induced glioma exosomes through myeloid-derived suppressor cells via the miR-10a/Rora and miR-21/Pten pathways.
Oncogene 2018;37:4239–4259.
14. Wu XR, Kong XP, Pellicer A, Kreibich G, Sun TT. Uroplakins in urothelial biology, function, and disease.
Kidney Int 2009;75:1153–1165.
15. Hiemstra TF, Charles PD, Gracia T, et al. Human urinary exosomes as innate immune effectors.
J Am Soc Nephrol 2014;25:2017–2027.
16. Miao Y, Li G, Zhang X, Xu H, Abraham SN. A TRP channel senses lysosome neutralization by pathogens to trigger their expulsion.
Cell 2015;161:1306–1319.
17. Bochon B, Kozubska M, Surygała G, et al. Mesenchymal stem cells-potential applications in kidney diseases.
Int J Mol Sci 2019;20:2462.
18. Ranghino A, Bruno S, Bussolati B, et al. The effects of glomerular and tubular renal progenitors and derived extracellular vesicles on recovery from acute kidney injury.
Stem Cell Res Ther 2017;8:24.
19. Gheldof D, Haguet H, Dogné JM, et al. Procoagulant activity of extracellular vesicles as a potential biomarker for risk of thrombosis and DIC in patients with acute leukaemia.
J Thromb Thrombolysis 2017;43:224–232.
20. Ammollo CT, Semeraro F, Milella RA, Antonacci D, Semeraro N, Colucci M. Grape intake reduces thrombin generation and enhances plasma fibrinolysis. Potential role of circulating procoagulant microparticles.
J Nutr Biochem 2017;50:66–73.
21. Skotland T, Hessvik NP, Sandvig K, Llorente A. Exosomal lipid composition and the role of ether lipids and phosphoinositides in exosome biology.
J Lipid Res 2019;60:9–18.
22. Del Conde I, Shrimpton CN, Thiagarajan P, López JA. Tissue-factor-bearing microvesicles arise from lipid rafts and fuse with activated platelets to initiate coagulation.
Blood 2005;106:1604–1611.
23. Yu M, Xie R, Zhang Y, et al. Phosphatidylserine on microparticles and associated cells contributes to the hypercoagulable state in diabetic kidney disease.
Nephrol Dial Transplant 2018;33:2115–2127.
24. He Z, Zhang Y, Cao M, et al. Increased phosphatidylserine-exposing microparticles and their originating cells are associated with the coagulation process in patients with IgA nephropathy.
Nephrol Dial Transplant 2016;31:747–759.
25. Berckmans RJ, Lacroix R, Hau CM, Sturk A, Nieuwland R. Extracellular vesicles and coagulation in blood from healthy humans revisited.
J Extracell Vesicles 2019;8:1688936.
26. Abid Hussein MN, Böing AN, Sturk A, Hau CM, Nieuwland R. Inhibition of microparticle release triggers endothelial cell apoptosis and detachment.
Thromb Haemost 2007;98:1096–1107.
27. Miyazawa B, Trivedi A, Togarrati PP, et al. Regulation of endothelial cell permeability by platelet-derived extracellular vesicles.
J Trauma Acute Care Surg 2019;86:931–942.
28. Taraboletti G, D'Ascenzo S, Borsotti P, Giavazzi R, Pavan A, Dolo V. Shedding of the matrix metalloproteinases MMP-2, MMP-9, and MT1-MMP as membrane vesicle-associated components by endothelial cells.
Am J Pathol 2002;160:673–680.
29. Lombardo G, Dentelli P, Togliatto G, et al. Activated STAT5 trafficking via endothelial cell-derived extracellular vesicles controls IL-3 pro-angiogenic paracrine action.
Sci Rep 2016;6:25689.
30. van Balkom BW, de Jong OG, Smits M, et al. Endothelial cells require miR-214 to secrete exosomes that suppress senescence and induce angiogenesis in human and mouse endothelial cells.
Blood 2013;121:3997–4006.
31. Anderson JD, Johansson HJ, Graham CS, et al. Comprehensive proteomic analysis of mesenchymal stem cell exosomes reveals modulation of angiogenesis via nuclear factor-kappaB signaling.
Stem Cells 2016;34:601–613.
32. Shabbir A, Cox A, Rodriguez-Menocal L, Salgado M, Van Badiavas E. Mesenchymal stem cell exosomes induce proliferation and migration of normal and chronic wound fibroblasts, and enhance angiogenesis in vitro.
Stem Cells Dev 2015;24:1635–1647.
33. Jella KK, Yu L, Yue Q, Friedman D, Duke BJ, Alli AA. Exosomal GAPDH from proximal tubule cells regulate ENaC activity.
PLoS One 2016;11:e0165763.
34. Street JM, Birkhoff W, Menzies RI, Webb DJ, Bailey MA, Dear JW. Exosomal transmission of functional aquaporin 2 in kidney cortical collecting duct cells.
J Physiol 2011;589:6119–6127.
35. Jeon JS, Kim E, Bae YU, et al. microRNA in extracellular vesicles released by damaged podocytes promote apoptosis of renal tubular epithelial cells.
Cells 2020;9:1409.
36. Munkonda MN, Akbari S, Landry C, et al. Podocyte-derived microparticles promote proximal tubule fibrotic signaling via p38 MAPK and CD36.
J Extracell Vesicles 2018;7:1432206.
37. Sonoda H, Lee BR, Park KH, et al. miRNA profiling of urinary exosomes to assess the progression of acute kidney injury.
Sci Rep 2019;9:4692.
38. Mortaza S, Martinez MC, Baron-Menguy C, et al. Detrimental hemodynamic and inflammatory effects of microparticles originating from septic rats.
Crit Care Med 2009;37:2045–2050.
39. Lv LL, Feng Y, Wu M, et al. Exosomal miRNA-19b-3p of tubular epithelial cells promotes M1 macrophage activation in kidney injury.
Cell Death Differ 2020;27:210–226.
40. Lv LL, Feng Y, Wen Y, et al. Exosomal CCL2 from tubular epithelial cells is critical for albumin-induced tubulointerstitial inflammation.
J Am Soc Nephrol 2018;29:919–935.
41. Li ZL, Lv LL, Tang TT, et al. HIF-1α inducing exosomal microRNA-23a expression mediates the cross-talk between tubular epithelial cells and macrophages in tubulointerstitial inflammation.
Kidney Int 2019;95:388–404.
42. Wu XM, Gao YB, Cui FQ, Zhang N. Exosomes from high glucose-treated glomerular endothelial cells activate mesangial cells to promote renal fibrosis.
Biol Open 2016;5:484–491.
43. Zhou Y, Xiong M, Fang L, et al. miR-21-containing microvesicles from injured tubular epithelial cells promote tubular phenotype transition by targeting PTEN protein.
Am J Pathol 2013;183:1183–1196.
44. Jia Y, Zheng Z, Guan M, et al. Exendin-4 ameliorates high glucose-induced fibrosis by inhibiting the secretion of miR-192 from injured renal tubular epithelial cells.
Exp Mol Med 2018;50:1–13.
45. Zhang L, He S, Guo S, et al. Down-regulation of miR-34a alleviates mesangial proliferation in vitro and glomerular hypertrophy in early diabetic nephropathy mice by targeting GAS1.
J Diabetes Complications 2014;28:259–264.
46. He Z, Guan X, Liu Y, et al. Alteration of exosomes secreted from renal tubular epithelial cells exposed to high-concentration oxalate.
Oncotarget 2017;8:92635–92642.
47. Singhto N, Kanlaya R, Nilnumkhum A, Thongboonkerd V. Roles of macrophage exosomes in immune response to calcium oxalate monohydrate crystals.
Front Immunol 2018;9:316.
48. Singhto N, Thongboonkerd V. Exosomes derived from calcium oxalate-exposed macrophages enhance IL-8 production from renal cells, neutrophil migration and crystal invasion through extracellular matrix.
J Proteomics 2018;185:64–76.
49. Grange C, Tapparo M, Collino F, et al. Microvesicles released from human renal cancer stem cells stimulate angiogenesis and formation of lung premetastatic niche.
Cancer Res 2011;71:5346–5356.
50. Xia Y, Zhang Q, Zhen Q, et al. Negative regulation of tumor-infiltrating NK cell in clear cell renal cell carcinoma patients through the exosomal pathway.
Oncotarget 2017;8:37783–37795.
51. Qu L, Ding J, Chen C, et al. Exosome-transmitted lncARSR promotes sunitinib resistance in renal cancer by acting as a competing endogenous RNA.
Cancer Cell 2016;29:653–668.
52. Lee SA, Cozzi M, Bush EL, Rabb H. Distant organ dysfunction in acute kidney injury: a review.
Am J Kidney Dis 2018;72:846–856.
53. Salih M, Demmers JA, Bezstarosti K, et al. Proteomics of urinary vesicles links plakins and complement to polycystic kidney disease.
J Am Soc Nephrol 2016;27:3079–3092.
54. du Cheyron D, Daubin C, Poggioli J, et al. Urinary measurement of Na+/H+ exchanger isoform 3 (NHE3) protein as new marker of tubule injury in critically ill patients with ARF.
Am J Kidney Dis 2003;42:497–506.
55. Zhou H, Pisitkun T, Aponte A, et al. Exosomal Fetuin-A identified by proteomics: a novel urinary biomarker for detecting acute kidney injury.
Kidney Int 2006;70:1847–1857.
56. Zhou H, Cheruvanky A, Hu X, et al. Urinary exosomal transcription factors, a new class of biomarkers for renal disease.
Kidney Int 2008;74:613–621.
57. Panich T, Chancharoenthana W, Somparn P, Issara-Amphorn J, Hirankarn N, Leelahavanichkul A. Urinary exosomal activating transcriptional factor 3 as the early diagnostic biomarker for sepsis-induced acute kidney injury.
BMC Nephrol 2017;18:10.
58. Li W, Yang S, Qiao R, Zhang J. Potential value of urinary exosome-derived let-7c-5p in the diagnosis and progression of type II diabetic nephropathy.
Clin Lab 2018;64:709–718.
59. Yamamoto CM, Murakami T, Oakes ML, et al. Uromodulin mRNA from urinary extracellular vesicles correlate to kidney function decline in type 2 diabetes mellitus.
Am J Nephrol 2018;47:283–291.
60. Prabu P, Rome S, Sathishkumar C, et al. MicroRNAs from urinary extracellular vesicles are non-invasive early biomarkers of diabetic nephropathy in type 2 diabetes patients with the 'Asian Indian phenotype'.
Diabetes Metab 2019;45:276–285.
61. Feng Y, Lv LL, Wu WJ, et al. Urinary exosomes and exosomal CCL2 mRNA as biomarkers of active histologic injury in IgA nephropathy.
Am J Pathol 2018;188:2542–2552.
62. Fan Q, Lu R, Zhu M, et al. Serum miR-192 is related to tubulointerstitial lesion and short-term disease progression in IgA nephropathy.
Nephron 2019;142:195–207.
63. Guo N, Zhou Q, Huang X, et al. Identification of differentially expressed circulating exosomal lncRNAs in IgA nephropathy patients.
BMC Immunol 2020;21:16.
64. Huang Z, Zhang Y, Zhou J, Zhang Y. Urinary exosomal miR-193a can be a potential biomarker for the diagnosis of primary focal segmental glomerulosclerosis in children.
Biomed Res Int 2017;2017:7298160.
65. Chen T, Wang C, Yu H, et al. Increased urinary exosomal microRNAs in children with idiopathic nephrotic syndrome.
EBioMedicine 2019;39:552–561.
66. Alvarez S, Suazo C, Boltansky A, et al. Urinary exosomes as a source of kidney dysfunction biomarker in renal transplantation.
Transplant Proc 2013;45:3719–3723.
67. Zhang H, Huang E, Kahwaji J, et al. Plasma exosomes from HLA-sensitized kidney transplant recipients contain mRNA transcripts which predict development of antibody-mediated rejection.
Transplantation 2017;101:2419–2428.
68. Park J, Lin HY, Assaker JP, et al. Integrated kidney exosome analysis for the detection of kidney transplant rejection.
ACS Nano 2017;11:11041–11046.
69. Lim JH, Lee CH, Kim KY, et al. Novel urinary exosomal biomarkers of acute T cell-mediated rejection in kidney transplant recipients: a cross-sectional study.
PLoS One 2018;13:e0204204.
70. Keri KC, Regner KR, Dall AT, Park F. Urinary exosomal expression of activator of G protein signaling 3 in polycystic kidney disease.
BMC Res Notes 2018;11:359.
71. Solé C, Cortés-Hernández J, Felip ML, Vidal M, Ordi-Ros J. miR-29c in urinary exosomes as predictor of early renal fibrosis in lupus nephritis.
Nephrol Dial Transplant 2015;30:1488–1496.
72. Tangtanatakul P, Klinchanhom S, Sodsai P, et al. Down-regulation of let-7a and miR-21 in urine exosomes from lupus nephritis patients during disease flare.
Asian Pac J Allergy Immunol 2019;37:189–197.
73. Li Y, Xu X, Tang X, et al. MicroRNA expression profile of urinary exosomes in Type IV lupus nephritis complicated by cellular crescent.
J Biol Res (Thessalon) 2018;25:16.
74. Chun-Yan L, Zi-Yi Z, Tian-Lin Y, et al. Liquid biopsy biomarkers of renal interstitial fibrosis based on urinary exosome.
Exp Mol Pathol 2018;105:223–228.
75. Lange T, Artelt N, Kindt F, et al. MiR-21 is up-regulated in urinary exosomes of chronic kidney disease patients and after glomerular injury.
J Cell Mol Med 2019;23:4839–4843.
76. Khurana R, Ranches G, Schafferer S, et al. Identification of urinary exosomal noncoding RNAs as novel biomarkers in chronic kidney disease.
RNA 2017;23:142–152.
77. Dias F, Teixeira AL, Nogueira I, et al. Extracellular vesicles enriched in hsa-miR-301a-3p and hsa-miR-1293 dynamics in clear cell renal cell carcinoma patients: potential biomarkers of metastatic disease.
Cancers (Basel) 2020;12:1450.
78. Dias F, Teixeira AL, Nogueira I, et al. Plasma extracellular vesicle-derived TIMP-1 mRNA as a prognostic biomarker in clear cell renal cell carcinoma: a pilot study.
Int J Mol Sci 2020;21:4624.
79. Jiang XC, Gao JQ. Exosomes as novel bio-carriers for gene and drug delivery.
Int J Pharm 2017;521:167–175.
80. Marcus ME, Leonard JN. FedExosomes: engineering therapeutic biological nanoparticles that truly deliver.
Pharmaceuticals (Basel) 2013;6:659–680.
81. Kato M. Noncoding RNAs as therapeutic targets in early stage diabetic kidney disease.
Kidney Res Clin Pract 2018;37:197–209.
82. Tang TT, Lv LL, Wang B, et al. Employing macrophage-derived microvesicle for kidney-targeted delivery of dexamethasone: an efficient therapeutic strategy against renal inflammation and fibrosis.
Theranostics 2019;9:4740–4755.
83. Kalinec GM, Gao L, Cohn W, Whitelegge JP, Faull KF, Kalinec F. Extracellular vesicles from auditory cells as nanocarriers for anti-inflammatory drugs and pro-resolving mediators.
Front Cell Neurosci 2019;13:530.
84. Yim N, Ryu SW, Choi K, et al. Exosome engineering for efficient intracellular delivery of soluble proteins using optically reversible protein-protein interaction module.
Nat Commun 2016;7:12277.
85. Choi H, Kim Y, Mirzaaghasi A, et al. Exosome-based delivery of super-repressor IκBα relieves sepsis-associated organ damage and mortality.
Sci Adv 2020;6:eaaz6980.
86. Gatti S, Bruno S, Deregibus MC, et al. Microvesicles derived from human adult mesenchymal stem cells protect against ischaemia-reperfusion-induced acute and chronic kidney injury.
Nephrol Dial Transplant 2011;26:1474–1483.
87. Choi HY, Moon SJ, Ratliff BB, et al. Microparticles from kidney-derived mesenchymal stem cells act as carriers of proangiogenic signals and contribute to recovery from acute kidney injury.
PLoS One 2014;9:e87853.
88. He J, Wang Y, Lu X, et al. Micro-vesicles derived from bone marrow stem cells protect the kidney both in vivo and in vitro by microRNA-dependent repairing.
Nephrology (Carlton) 2015;20:591–600.
89. Choi HY, Lee HG, Kim BS, et al. Mesenchymal stem cell-derived microparticles ameliorate peritubular capillary rarefaction via inhibition of endothelial-mesenchymal transition and decrease tubulointerstitial fibrosis in unilateral ureteral obstruction.
Stem Cell Res Ther 2015;6:18.
90. Wang B, Yao K, Huuskes BM, et al. Mesenchymal stem cells deliver exogenous microRNA-let7c via exosomes to attenuate renal fibrosis.
Mol Ther 2016;24:1290–1301.
91. Nagaishi K, Mizue Y, Chikenji T, et al. Mesenchymal stem cell therapy ameliorates diabetic nephropathy via the paracrine effect of renal trophic factors including exosomes.
Sci Rep 2016;6:34842.
92. Jiang ZZ, Liu YM, Niu X, et al. Exosomes secreted by human urine-derived stem cells could prevent kidney complications from type I diabetes in rats.
Stem Cell Res Ther 2016;7:24.
93. Pan T, Jia P, Chen N, et al. Delayed remote ischemic preconditioning confersrenoprotection against septic acute kidney injury via exosomal miR-21.
Theranostics 2019;9:405–423.
94. Dominguez JH, Liu Y, Gao H, et al. Renal tubular cell-derived extracellular vesicles accelerate the recovery of established renal ischemia reperfusion injury.
J Am Soc Nephrol 2017;28:3533–3544.
95. Dominguez JM 2nd, Dominguez JH, Xie D, Kelly KJ. Human extracellular microvesicles from renal tubules reverse kidney ischemia-reperfusion injury in rats.
PLoS One 2018;13:e0202550.
96. Yuana Y, Levels J, Grootemaat A, Sturk A, Nieuwland R. Co-isolation of extracellular vesicles and high-density lipoproteins using density gradient ultracentrifugation.
J Extracell Vesicles 2014 3:10.3402/jev.v3.23262.
97. Baranyai T, Herczeg K, Onódi Z, et al. Isolation of exosomes from blood plasma: qualitative and quantitative comparison of ultracentrifugation and size exclusion chromatography methods.
PLoS One 2015;10:e0145686.
98. Yang B, Chen Y, Shi J. Exosome biochemistry and advanced nanotechnology for next-generation theranostic platforms.
Adv Mater 2019;31:e1802896.
99. Yang Z, Shi J, Xie J, et al. Large-scale generation of functional mRNA-encapsulating exosomes via cellular nanoporation.
Nat Biomed Eng 2020;4:69–83.
100. Mossberg M, Ståhl AL, Kahn R, et al. C1-inhibitor decreases the release of vasculitis-like chemotactic endothelial microvesicles.
J Am Soc Nephrol 2017;28:2472–2481.